A case of T-cell lymphoproliferative disorder associated with hypereosinophilia with excellent response to mycophenolate mofetil
Author(s) -
Amr Hanbali,
Marwan Shaheen,
Feras Alfraih,
Wafa Alotaibi,
Riad El Fakih,
Tarek Owaidah,
Syed Osman Ahmed
Publication year - 2017
Publication title -
hematology/oncology and stem cell therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 22
eISSN - 1658-3876
pISSN - 2589-0646
DOI - 10.1016/j.hemonc.2016.11.001
Subject(s) - hypereosinophilia , medicine , hypereosinophilic syndrome , eosinophilia , eosinophil , mycophenolate , immunology , lymphoproliferative disorders , rituximab , dermatology , pathology , lymphoma , transplantation , asthma
Hypereosinophilic syndrome (HES) is a group of rare blood disorders characterized by a persistent elevation of blood eosinophil count ⩾1.5×10 9 /L and clinical manifestations attributable to eosinophilia or tissue hypereosinophilia. Lymphocytic variant of HES (HES-L) is a known subtype according to World Health Organization classification. It is well documented in the literature that patients with HES-L are predisposed to develop T-cell lymphoma. We report a case of T-cell lymphoproliferation associated with hypereosinophilia, which has been successfully treated with mycophenolate mofetil, with resolution of skin lesions and normalization of eosinophil count and immunoglobulin E level. We believe this is a clinically relevant case since this is a rare disease with little known knowledge on its best treatment modality.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom